NIH | National Cancer Institute | NCI Wiki  

You are viewing an old version of this page. View the current version.

Compare with Current View Page History

Version 1 Next »

Date

Attendees

Committee MemberPresentAbsent
Kuffel, Gina (NIH/NCI) [C]
X
Amy Leblanc

Otridge, John (NIH/NCI) [C]



Kim, Erika (NIH/NCI) [E]


Sommers, Connie (NIH/NCI) [E]



Debbie Knapp

Toby Hecht

Ralph Parchment

Goals

  • Discuss updates to ICDC and define emerging strategies and priorities

SharePoint Site

https://nih.sharepoint.com/sites/NCI-CBIIT-FNL-ICDC-ICDCLeadershipGroups

Outstanding Action Items


  • Revisit new steering committee members in September (loop Connie into this discussion) 

Agenda

ItemWhoTalking Points
New Steering Committee Members



Post Discussion about FidoCure

All


New ICDC Subcommittee: Longitudinal Data Acquisition and Use Working Group (LDAUWG)

Purpose: Formulate scientific questions and use cases that can be used to interrogate longitudinal datasets that would justify the ingestion of such data into the ICDC.. 

All

DGAB Updates

Kuffel, Gina (NIH/NCI) [C] 

ICDC Studies in Active Submission

  • COTC021
    • "Evaluation of Orally Administered mTOR inhibitor Rapamycin in Dogs in the Adjuvant Setting with Osteosarcoma"
    • Dr. Amy LeBlanc
    • Status: Files have been transferred, but they are not in the requested format
  • UBC03
    • "Transcriptomic analyses of early stage bladder cancer in Scottish Terriers detected through screening"
    • Dr. Debbie Knapp
    • Status: Metadata transfer is in progress
  • OSA02
    • "Immune Pathways and TP53 missense mutations are associated with longer survival in canine osteosarcoma"
    • Dr. Dawn Duval
    • Status: Files and metadata have been received and are in review
ICDC Biospecimen Data

Kuffel, Gina (NIH/NCI) [C] 

Upcoming Steering Committee Meeting

Ralph Parchment

  • February meeting: Tuesday February 20th

Minutes (Not Verbatim)





Previous ICDC Use Cases from Steering Committee

1. Genomic correlates across platforms (DNA, RNA, protein).

2. Correlating multi-omics data with clinical annotation and phenotypes, particularly outcomes.

3. Comparative analyses of canine and human. Examples include:

1. Search for conserved mutations between canine and human tumors

2. Disease diagnosis (e.g. cancer type) and classification mapping between canines and humans

5. Gene expression changes and mutational profiles associated with therapeutic response and outcome

6. How do sporadic tumors in non-human mammals compare to sporadic human tumors?

7. Correlations and model building from radiomic and pathomic features extracted from medical and histopathologic images with outcomes and genomics, as is currently being widely done with human images

8. Develop biomarkers of response and resistance in humans by analyzing the responses and genomic signatures in dogs.

Action items

  • Toby to invite Greg from CCDI to the next Executive Team Meeting in January
  • Toby to look across the NCI directory to find person that has a combination of canine and pediatric oncology background
  • No labels